NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple ...

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with ...

Biogen Idec has partnered with Google X, Google's business unit for long-term “moonshot” projects, to study outside factors that might contribute to the progression of multiple sclerosis (MS), ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

(Reuters) -Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis. Its ...

Biogen booked sales of $2.39 billion for the quarter, down 6% from the same period a year ago. It reported net income of $249.7 million, or $1.71 per share, for the fourth quarter, down from net ...

“ Biogen believes the voluntary worldwide withdrawal of ZINBRYTA, a treatment for relapsing multiple sclerosis, is in the best interest of patients,” said Alfred Sandrock, M.D., Ph.D., executive vice ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Biogen BIIB announced that it has entered into a license and collaboration agreement with China-based biopharmaceutical company InnoCare for orelabrutinib, an oral small molecule Bruton’s tyrosine ...

Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago. The company recorded charges related to dropping its controversial Alzheimer's drug Aduhelm and as said sales ...